Implementation of cost-effective alternatives and advancements in diagnostic and therapeutic processes
| PI | GROUP | |
| Carmina Díaz | [GIN]: 1 | Neurosciences Research |
| TITLE | Intramuscular infusion of autologous bone marrow-derived stem cells in patients with Amyotrophic Lateral Sclerosis | |
| YEAR | 2019-2022 | |
| REFERENCE PROJECT/PUBLICATION | TCIM – ELA II. EudraCT number: 2019-002302-46 | |
| DESCRIPTION | Intramuscular stem cell infusion to prolong the survival of anterior horn motor neurons. Trial funded by the ISCIII, sponsored by FFIS-IMIB. Application of knowledge derived from experimental studies on cell therapy in ALS models at the Alicante Neuroscience Institute. | |
| IMPLEMENTATION/IMPACT | Phase II multicenter clinical trial | |
| TITLE |
Validation and optimization of alpha-synuclein (α-syn) determination in cerebrospinal fluid as a biomarker for the early and differential diagnosis of Alzheimer’s disease versus synucleinopathies. |
|
| AÑO | 2019 | |
| REFERENCE PROJECT/PUBLICATION | DG for Universities, Research and Science, GVA (AICO/2018/090 to JSV), CIBERNED, ISCIII (FEDER, ‘Investing in your future’). | |
| DESCRIPTION | Improvement in the differential diagnosis at the mild cognitive impairment stage in patients with Alzheimer’s disease compared to patients with Lewy body dementia. | |
| IMPLEMENTATION/IMPACT | Redesign of ELISA protocols for the determination of α-syn in the CSF, design of alternative kits for differential diagnosis. | |
| PI | GROUP | ||
| Jesús Vioque | [GIN]: 35 | Nutritional Epidemiology | |
| TITLE |
Food Frequency Questionnaires (FFQ) PLOS ONE | DOI:10.1371/journal.pone.0167338 Nutrients 2019, 11, 933; doi:10.3390/nu11040933 |
||
| YEAR | 2019 | ||
| PROYECTO/PUBLICACIÓN DE REFERENCIA | Red INMA G03/176; CB06/02/0041; FIS 97/0588; 00/0021-2, PI061756; PS0901958; FIS-FEDER 03/1615, 04/1509, 04/1112, 04/1931, 05/1079, 05/1052, 06/1213, 07/0314; 09/02647; FIS-PI041436, FIS- PI081151, FIS-PI06/0867; FIS-PS09/00090, FIS-PI042018, FIS-PI09 02311, FIS PI11/01007, FISPI13/02429, FISPI16/1288, FISPI17/00260), Fundació la Marato TV3 (201622 10), Miguel Servet-FEDER CP15/0025, FPU14/00046. | ||
| DESCRIPTION | Validación de cuestionarios FFQ para la evaluación dietética de una amplia gama de nutrientes y grupos de alimentos en población pediátrica (cohorte INMA) | ||
| IMPLEMENTATION/IMPACT | Registro y licencia de uso | ||
| PI | GROUP | |
| Joaquín Portilla | [GIN]: 2 | Infectious Diseases Research |
| PI | GROUP | |
| Luis Hernández | [GIN]: 7 | Translational Research in Respiratory Diseases |
| PI | GROUP | |
| Francisco Javier Pérez | [GIN]: 13 | Nephrology Research |
| PI | GROUP | |
| Isabel Betlloch | [GIN]: 18 | Research in Medical-Surgical Dermatology |
| PI | GROUP | |
| Luis Moral | [GIN]: 38 | Research in Pediatrics and Clinical Pharmacology |
| TITLE | ANAMNESIS INTERVIEW FOR THE DETECTION OF AUTISM SPECTRUM DISORDERS (ASD) | |
| YEAR | 2019 | |
| REFERENCE PROJECT/PUBLICATION | Trastea: Comprehensive Care Document for Autism Spectrum Disorder. | |
| DESCRIPTION | Incorporation of specific content into the general anamnesis interview to be conducted by “front-line professionals” (Primary Care pediatricians). This content is designed to identify indirect signs of ASD during early developmental stages, thereby streamlining the diagnosis following referral to the appropriate specialist. | |
| IMPLEMENTATION/IMPACT | Currently in the implementation phase. Incorporated into the PIR (Resident Intern Psychologist) training program of the Pediatric Psychology Unit. | |
| PI | GROUP | |
| Paloma Vela | [GIN]: 16 | Research in Musculoskeletal System Pathology |
| TITLE |
EVALUATION OF THE IMPLEMENTATION OF ASSOCIATED RISK MANAGEMENT RECOMMENDATIONS FOR THE USE OF BIOLOGIC THERAPIES IN THE RHEUMATOLOGY DEPARTMENT OF THE ALICANTE GENERAL UNIVERSITY HOSPITAL: FIVE-YEAR FOLLOW-UP AFTER THE FIRST EVALUATION |
|
| YEAR | 2019-2021 (in progress) | |
| REFERENCE PROJECT/PUBLICATION | 6th Call for Grants to Support and Promote Research, ISABIAL 2019 | |
| DESCRIPTION | To evaluate the outcome of implementing a vaccination programme 5 years ago in patients receiving biologic drugs with incomplete or absent vaccination. Also, to compare the vaccination status of patients to whom improvement measures were applied with the vaccination status of patients diagnosed and treated subsequently. | |
| IMPLEMENTATION/IMPACT | In progress (comparing the new results with those from 5 years ago). | |
| TITLE | DETECTION OF DEFICITS IN RISK CONTROL IN CHRONIC ARTHRITIS THROUGH THE IMPLEMENTATION OF A NURSE-LED PROGRAMME | |
| YEAR | 2019-2021 (in progress) | |
| REFERENCE PROJECT/PUBLICATION | 6th Call for Grants to Support and Promote Research, ISABIAL 2019 | |
| DESCRIPTION |
– Quantify and identify deficiencies in risk control in patients with chronic arthritis treated with biologic drugs in routine clinical practice, through the implementation of a nurse-led programme in rheumatology clinics. – Evaluate the actions undertaken by the rheumatologist after applying the programme. – Evaluate the programme’s effectiveness one year after its implementation |
|
| IMPLEMENTATION/IMPACT | Implementation of a nursing programme that makes it possible to correct deficits that exist in clinical practice, in routine medical consultations, both in risk control and in the detection and management of comorbidities. It will improve the management of these patients, their safety and, consequently, provide higher-quality care. | |
| TITLE | BIOBADASER Phase III | |
| YEAR | 2015–in progress | |
| REFERENCE PROJECT/PUBLICATION | FER-ADA-2015-01 | |
| DESCRIPTION | BIOBADASER Phase III is a prospective follow-up study of adverse events and safety in biologic and biosimilar treatments in patients with rheumatologic diseases | |
| IMPLEMENTATION/IMPACT | This study will make it possible to identify adverse events that occur during the treatment of rheumatic diseases with biologic therapies and biosimilar medicines, estimate their frequency, identify unexpected adverse events, and identify adverse events that occur after treatment discontinuation. | |
| TITLE | Cardiovascular and extension ultrasound evolution in new patients with gout | |
| YEAR | 2019–ongoing | |
| REFERENCE PROJECT/PUBLICATION |
UGP-18-043 Research Support Grant in Rheumatology from the Valencian Rheumatology Foundation (FVR) 2018 RESEARCH PROMOTION PLAN. FER GRANTS 2017 (Spanish Foundation of Rheumatology) |
|
| DESCRIPTION | Study aimed at conducting a prospective cardiovascular ultrasound assessment of new patients with gout | |
| IMPLEMENTATION/IMPACT | This study aims to prospectively evaluate patients with gout from the perspective of carotid ultrasound atherosclerosis, seeking to establish the impact of gout treatment itself and its consequences (crystal dissolution) on such evolution. The results may potentially confirm the cardiovascular benefit of appropriate gout management, which to date remains controversial. | |
| PI | GROUP | |
| Rodrigo Jover | [GIN]: 6 | Colorectal Cancer Research: Prevention and Management |
| TITLE | Definition of diagnostic criteria in Lynch-like syndrome | |
| YEAR | 2013-2019 | |
| REFERENCE PROJECT/PUBLICATION | Rodríguez-Soler Gastroenterology 2013; Picó Clin Gastroenterol Hepatol 2019 | |
| DESCRIPTION | Definition of a new familial risk entity, characterised by the presence of colorectal cancer with suspected Lynch syndrome not confirmed by genetic testing | |
| IMPLEMENTATION/IMPACT | Surveillance strategies under the diagnostic criteria of the new entity | |
| TITLE | Post-polypectomy surveillance algorithm | |
| YEAR | 2012-2019 | |
| REFERENCE PROJECT/PUBLICATION | Atkin Endoscopy 2012; Hassan Endoscopy 2013; Mangas-Sanjuan Gastroenterol Hepatol 2019 | |
| DESCRIPTION | Participation in European and national clinical practice guidelines that define the surveillance algorithm after removal of colon polyps | |
| IMPLEMENTATION/IMPACT | Participation in and leadership of past and current post-polypectomy surveillance algorithms in our country | |
| PI | GROUP | |
| Enrique de-Madaria | [GEM]: 25 | Clinical Research in Pancreatology |
| PI | GROUP | |
| Celia Villodre | [GEM]: 32 | Surgical Audit Research |
| TITLE |
Risk scales for morbidity in community-acquired emergency gastrointestinal surgery. Comparison between open and laparoscopic approaches. Prospective, multicentre Spanish study. Am J Surg. 2016 Nov;212(5):917-926 |
|
| YEAR | In progress (2017-2019) | |
| REFERENCE PROJECT/PUBLICATION |
LUCENTUM Alicante Surgical Community Emergencies New Tool for the enUmeration of Morbidities: a simplified auditing tool for community-acquired gastrointestinal surgical emergencies. |
|
| DESCRIPTION | LUCENTUM is intended to be used as a tool for conducting surgical audits. It provides population adjustment according to the risk of morbidity and mortality. The main objective is to define risk-adjusted benchmark outcomes that make it possible to adopt measures to improve quality of care. | |
| IMPLEMENTATION/IMPACT | In progress (comparing the new results with benchmark standards). | |
| PI | GROUP | |
| Gloria Peiró | [GCL]: 9 | Breast Cancer Research |
| TITLE | Determination of biomarkers for stratifying patients at risk of death or local/distant recurrence, treatment response (trastuzumab, paclitaxel), and therapeutic targets | |
| YEAR | In progress (2006-2019) | |
| REFERENCE PROJECT/PUBLICATION |
1. Insulin-like growth factor 1 receptor (IGF-IR) and PTEN in patients with T1-2N0M0 breast cancer treated with breast-conserving therapy and radiotherapy. Correlation with local response and prognostic value (FIS 03/1411) 2. Predictive value of response to trastuzumab of growth factors and the PI3K/Akt signalling pathway in HER2+ breast cancer (FIS 06/1495) 3. Retrospective analysis of the PTEN/PI3K/Akt pathway and response to paclitaxel in early breast cancer with positive lymph nodes (FIS 06/1488) 4. Osteopontin-C: prognostic and/or predictive marker of response to trastuzumab in patients with HER2-positive breast cancer? FCVI-HGUA (2008-09) 5. Study of the expression of factors in the Hedgehog signalling pathway in cell lines representative of breast cancer immunophenotypes. FCVI-HGUA (2012/PC-08) 6. Inhibitor of Differentiation proteins (IDs): study of their regulatory function as biomarkers of “tumour stem cells” and of epithelial–mesenchymal transition in breast cancer. BIENVENIDA NAVARRO-LUCIANO TRIPODI FOUNDATION. 2016 (BOLA00150) 7. Immunity and breast cancer (IN PROGRESS): .- Analysis of immune checkpoints in co-cultures of breast cancer cell lines and mononuclear cells: pilot study. ISABIAL/FISABIO 2018 (NR-180172); 2018 (NR-180184) .- Relevance of immune checkpoints as biomarkers in breast cancer and their correlation with clinico-pathological factors. ISABIAL/FISABIO 2019 (NR-190292) .- Relevance of immune checkpoints as biomarkers in breast cancer and their correlation with clinico-pathological factors. 2019 (NR-190293) |
|
| DESCRIPTION | Studies of protein, RNA and mutational expression of IGF1R, PTEN/PI3K/Akt/mTOR, c-SRC, osteopontin, inhibitor of differentiation proteins (ID), FOXP3 and regulatory T cells (Treg), immune checkpoints | |
| IMPLEMENTATION/IMPACT | In progress (applicability as “therapeutic targets” in the context of Clinical Trials) | |
| PI | GROUP | |
| Juan Carlos Martínez | [GCL]: 19 | Gynaecological Neoplasms Research |
| PI | GROUP | |
| José Bañuls | [GCL]: 21 | Melanoma Research |
| PI | GROUP | |
| F. Javier Fernández Sánchez | [GCL]: 11 | Drug Allergy Research |
| TITLE | Beta-lactam Allergy in Elderly Patients | |
| YEAR | In progress since 2016 | |
| REFERENCE PROJECT/PUBLICATION | Teodorikez Wilfox Jimenez Rodriguez; Natalia Blanca Lopez; Maria Ruano Zaragoza; Victor Soriano Gomis; Angel Esteban Rodriguez; Geronima Riera Sendra; Antonio Palazon Bru; Miguel Blanca; Jose Manuel Ramos Rincon; Javier Fernandez Sanchez. Allergological Study of 565 Elderly Patients Previously Labeled as Allergic to Penicillins. Journal of Asthma and Allergy. 12, pp. 421 – 435. 26/12/2019. | |
| DESCRIPTION | Study of allergic reactions to penicillins in patients aged 60 years and older, to assess true reactivity and immunosenescence, as well as cost reduction by avoiding the penicillin allergy label. | |
| IMPLEMENTATION/IMPACT | Daily study of elderly patients and currently any patient over 14 years of age who is admitted to hospital for any condition and has the label or indicates that they have a penicillin allergy. | |
| TITLE | Determination of clinical criteria and biomarkers for the study of non-IgE-mediated food allergy (in English, Food protein-induced enterocolitis syndrome, FPIES) | |
| YEAR | In progress since 2012 | |
| REFERENCE PROJECT/PUBLICATION |
1. González-Delgado P, Caparrós E, Moreno MV, Clemente F, Flores E, Velásquez L, Rubio G, Fernández J. Clinical and immunological characteristics of a pediatric population with food protein-induced enterocolitis syndrome (FPIES) to fish. IF: 3,775. Pediatr Allergy Immunol. 2016 May;27(3):269-75. doi: 10.1111/pai.12529. 2. Moreno MV, Caparrós E, Fernández J, González-Delgado P. Immunologic study of two fruit-induced FPIES cases. Pediatr Allergy Immunol 2017 Aug 8.doi:10.1111/pai.12769. 3. Purificación Gonzalez-Delgado, Esther Caparrós, M. Victoria Moreno, Begoña Cueva, and Javier Fernández. Food protein induced enterocolitis-like syndrome in a population of adolescents and adults caused by seafood. J Allergy Clin Immunol Pract. 2019 7(2):670-672. doi: 10.1016/j.jaip.2018.07.028 PMID: 30075344 |
|
| DESCRIPTION | Clinical studies on the characteristics of FPIES, in both children and adults, and with foods other than those usually involved | |
| IMPLEMENTATION/IMPACT | Expanding knowledge of diseases within the spectrum of non-IgE-dependent food-related allergic diseases that affect a large number of people and are underdiagnosed. | |
| GROUP | TITLE | YEAR | REFERENCE PROJECT/PUBLICATION | DESCRIPTION | IMPLEMENTATION/IMPACT What has been the impact of the results? Has it been implemented in clinical practice, and how? |
| GROUP 1 | Creation of the spin-off company Tearful, S.L. | 2020 | Creation of a UMH spin-off company | Company activity: development of diagnostic equipment (patent application P201931176, 2019-12-30) | |
| GROUP 11 | DESENSITISATIONS TO CHEMOTHERAPEUTIC AGENTS | 2020 | Jimenez-Rodriguez TW; Berges-Gimeno M; Barranco R; et al;Muñoz-Cano R. 2021. Management of hypersensitivity reactions to chemotherapy and biologic agents: A survey of ARADyAL (Asthma, Allergic and Adverse Reactions Network) | Desensitisations to biologics and chemotherapeutic agents | |
| GROUP 11 | DELABELLING OF PENICILLIN ALLERGY | 2020-21 | TW Jimenez-Rodriguez; Natalia Blanca-Lopez; Maria Ruano-Zaragoza; et al; Javier Fernandez- Sanchez. 2019. Allergological Study of 565 Elderly Patients Previously Labeled as Allergic to Penicillins Journal of Asthma and Allergy. 12, pp.421-435. | Delabelling of all patients admitted with a penicillin allergy alert in the hospital | |
| GROUP 19 | SENTINEL LYMPH NODE IN ENDOMETRIAL CANCER | 2020 | IdiPAZ HULP Study Code: PI-1460 | Use of the sentinel lymph node as an intraoperative diagnostic procedure. High impact. YES, IT HAS BEEN IMPLEMENTED IN PRACTICE. | |
| GROUP 19 | Randomised, open-label, parallel-group clinical trial with a control group to explore the efficacy of PALOMACARE gel in repairing the cervico-vaginal mucosa with lesions caused by HPV (PALOMA Clinical Trial) | PHPC-201501 | Use of Papilocare Gel as an adjuvant in the treatment of certain preneoplastic lesions | ||
| GROUP 19 | Multicentre study to evaluate the diagnostic utility of the intraoperative human papillomavirus test as an early marker of cure or recurrence in women with high-grade cervical intraepithelial neoplasia (HSIL/CIN2-3) |
PR(AMI)131/2020 | Sampling for the study of HPV presence at the time of conisation. It has been incorporated into practice as a prognostic assessment method and for follow-up. |